Evaluation of Survival and Prognostic Factors in Our Glioblastoma Multiforme Patients: Retrospective Study

Süreyya Sarıhan

Makale detayları

Evaluation of Survival and Prognostic Factors in Our Glioblastoma Multiforme Patients: Retrospective Study

Yazarlar:

Süreyya Sarıhan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Sinirbilim | Onkoloji ve Karsinogenez

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.63-70

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291063

pISSN:

1300-414X

Anahtar kelimeler:

Özet:

 We aimed to evaluate survival and prognostic factors in our cases diagnosed with Glioblastoma Multiforme GBM. 69 cases treated with a median of 5980 cGy 3400-6090 radiotherapy RT between 2015 and 2020 were evaluated on August, 2021. The median follow-up was 12 months 2-68, and median age was 60 39-77. Total excision, subtotal excision and biopsy were performed in 81, 15 and 4 of patients, respectively. Concomitant or concomitant and adjuvant or adjuvant temozolomide TMZ was administered to 10 and 72 and 9 of cases, respectively. In the first evaluation after RT, there was 89 5663 local control and 11 progression 763. Neurological improvement was observed in 26 1038 of cases. Relapse was observed in a median of 7 months 3-46 in 80 of cases 5062 and 85 of cases 5566 were progressed at the last control. The median and 2-year overall survival OS was 12 months 3-69, and 17, while for disease-free survival DFS was 7 months 3-55, and 9, respectively, for all cases. The median OS 18 vs 5 months, p  0.005 and DFS 13 vs 5 months, p 0.022 were found better in those who received conventional RT and concomitant TMZ than those who received RT alone in univariate analysis. In the multivariate analysis, Karnofsky performance score  80 after RT,  5 courses of adjuvant TMZ, and RT dose  40 Gy were found significant for OS p  0.05. In a randomized study, 2-year OS was reported as 27 vs 11 in those who received conventional 60 Gy RT and concomitant TMZ compared RT alone. Conventional 60 Gy RT with concurrent and adjuvant TMZ is the standard treatment approach in patients with GBM who have good prognostic factors, and in our study, 2-year OS was obtained in 25 of these cases.

 We aimed to evaluate survival and prognostic factors in our cases diagnosed with Glioblastoma Multiforme GBM. 69 cases treated with a median of 5980 cGy 3400-6090 radiotherapy RT between 2015 and 2020 were evaluated on August, 2021. The median follow-up was 12 months 2-68, and median age was 60 39-77. Total excision, subtotal excision and biopsy were performed in 81, 15 and 4 of patients, respectively. Concomitant or concomitant and adjuvant or adjuvant temozolomide TMZ was administered to 10 and 72 and 9 of cases, respectively. In the first evaluation after RT, there was 89 5663 local control and 11 progression 763. Neurological improvement was observed in 26 1038 of cases. Relapse was observed in a median of 7 months 3-46 in 80 of cases 5062 and 85 of cases 5566 were progressed at the last control. The median and 2-year overall survival OS was 12 months 3-69, and 17, while for disease-free survival DFS was 7 months 3-55, and 9, respectively, for all cases. The median OS 18 vs 5 months, p  0.005 and DFS 13 vs 5 months, p 0.022 were found better in those who received conventional RT and concomitant TMZ than those who received RT alone in univariate analysis. In the multivariate analysis, Karnofsky performance score  80 after RT,  5 courses of adjuvant TMZ, and RT dose  40 Gy were found significant for OS p  0.05. In a randomized study, 2-year OS was reported as 27 vs 11 in those who received conventional 60 Gy RT and concomitant TMZ compared RT alone. Conventional 60 Gy RT with concurrent and adjuvant TMZ is the standard treatment approach in patients with GBM who have good prognostic factors, and in our study, 2-year OS was obtained in 25 of these cases.

 We aimed to evaluate survival and prognostic factors in our cases diagnosed with Glioblastoma Multiforme GBM. 69 cases treated with a median of 5980 cGy 3400-6090 radiotherapy RT between 2015 and 2020 were evaluated on August, 2021. The median follow-up was 12 months 2-68, and median age was 60 39-77. Total excision, subtotal excision and biopsy were performed in 81, 15 and 4 of patients, respectively. Concomitant or concomitant and adjuvant or adjuvant temozolomide TMZ was administered to 10 and 72 and 9 of cases, respectively. In the first evaluation after RT, there was 89 5663 local control and 11 progression 763. Neurological improvement was observed in 26 1038 of cases. Relapse was observed in a median of 7 months 3-46 in 80 of cases 5062 and 85 of cases 5566 were progressed at the last control. The median and 2-year overall survival OS was 12 months 3-69, and 17, while for disease-free survival DFS was 7 months 3-55, and 9, respectively, for all cases. The median OS 18 vs 5 months, p  0.005 and DFS 13 vs 5 months, p 0.022 were found better in those who received conventional RT and concomitant TMZ than those who received RT alone in univariate analysis. In the multivariate analysis, Karnofsky performance score  80 after RT,  5 courses of adjuvant TMZ, and RT dose  40 Gy were found significant for OS p  0.05. In a randomized study, 2-year OS was reported as 27 vs 11 in those who received conventional 60 Gy RT and concomitant TMZ compared RT alone. Conventional 60 Gy RT with concurrent and adjuvant TMZ is the standard treatment approach in patients with GBM who have good prognostic factors, and in our study, 2-year OS was obtained in 25 of these cases.

 Glioblastoma Multiforme GBM tanılı olgularımızda sağkalım ve prognostik faktörleri değerlendirmeyi amaçladık. 2015-2020 arasında ortanca 5980 cGy 3400-6090 radyoterapi RT ile tedavi edilmiş 69 olgu, Ağustos 2021de değerlendirildi. Ortanca izlem 12 ay 2-68 ve ortanca yaş 60 39-77 idi. Total eksizyon, subtotal eksizyon ve biyopsi sırasıyla, 81, 15 ve 4 hastaya uygulanmıştı. RT ile eşzamanlı veya eşzamanlı ve adjuvan veya adjuvan temozolomid TMZ, sırasıyla 10, 72 ve 9 olguya uygulandı. RT sonrası ilk değerlendirmede 89 5663 lokal kontrol, 11 progresyon 763 bulundu. Nörolojik düzelme 26 1038 olguda gözlendi. Nüks ortanca 7 ayda 3-46 80 5062 olguda gözlenmiş olup son kontrolde olguların 85si progrese idi 5566. Tüm olgular için ortanca ve 2 yıllık genel sağkalım GSK, 12 ay 3-69 ve 17 iken, hastalıksız sağkalım HSK sırasıyla, 7 ay 3-55 ve 9 bulundu. Univaryat analizde konvansiyonel RT ve eşzamanlı TMZ alanlarda, sadece RT alanlara göre ortanca GSK 18 vs 5 ay, p  0.005 ve HSK 13 vs 5 ay, p  0.002 daha iyi bulundu. Multivaryat analizde GSK için RT sonrası Karnofsky performans skoru  80 olması, adjuvan TMZ  5 kür almak, RT dozu  40 Gy anlamlı bulundu p  0,05. Stupp ve arkadaşları, randomize çalışma ile konvansiyonel 60 Gy RT, eşzamanlı ve adjuvan TMZ alanlarda tek başına RT alanlara göre 2 yıl GSKda anlamlı artış 27 vs 11 bildirmiştir. İyi prognostik faktörleri olan GBMli hastalarda, konvansiyonel 60 Gy RT ile eşzamanlı ve adjuvan TMZ, standart tedavi yaklaşımı olup çalışmamızda bu olgularda 2 yıllık GSK 25 oranında elde edilmiştir.

Makale detayları

Evaluation of Survival and Prognostic Factors in Our Glioblastoma Multiforme Patients: Retrospective Study

Yazarlar:

Süreyya Sarıhan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Sinirbilim | Onkoloji ve Karsinogenez

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.63-70

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291063

pISSN:

1300-414X

surgery

radiotherapy

temozolomide

survivalGlioblastoma multiforme

cerrahi

radyoterapi

temozolomid

sağkalım

surgery

radiotherapy

temozolomide

survival

Sayı

Makale detayları

Yazarlar: Süreyya Sarıhan

Yayıncı: Bursa Uludağ University

Ana Başlıklar: Sinirbilim | Onkoloji ve Karsinogenez

Dergi: Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.63-70

Belge Tipi: Makale

Yayın Tarihi: 9/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001291063

pISSN: 1300-414X

Sayı

Yazarlar:

Süreyya Sarıhan

Yayıncı:

Bursa Uludağ University

Ana Başlıklar:

Sinirbilim | Onkoloji ve Karsinogenez

Dergi:

Uludağ Üniversitesi Tıp Fakültesi Dergisi Vol.49 Issue 1, pp.63-70

Belge Tipi:

Makale

Yayın Tarihi:

9/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001291063

pISSN:

1300-414X